A Commitments and Accountability
A1 The company publishes a global access plan for its product
A2 The company commits to comply with human rights standards in relation to poduct development and marketing
C International cooperation
C1 The company commits to C-TAP or MPP
C2 The company commits to not enforcing the exclusive rights of Covid-19 related patents
C3 The company supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator
C4 The company agrees to license its Covid-19 medical products to other companies
E Equality, non-discrimination & equity
E1 The company makes the active ingredient available on reasonable ground. [Only for therapeutics]
E2 The company commits to full technology transfer to other manufacturers
E3 The company commits to non-profit, ‘fair’, or differential pricing
E4 The company equitably distributes supplies globally. [Only applies to vaccines]
E5 The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable]
E6 The company agrees to waive exclusive rights in regulatory test data [where applicable].
T1 The company publishes its R&D costs.
T2 The company publishes its profit margin.
T3 The company publishes the average and/or marginal costs of production.
T4 The company publishes its production capacity.
T5 The company publishes the public subsidies it received during product development and/or testing.
T6 The company publishes the text of licensing agreements.
T7 The company registers its clinical trials in public repositories.